Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Management to host conference call at 4:30 pm ET on that day BOCA RATON, Florida, July 28, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology...
-
Phase 2 study of XProTM will be a six-month, blinded, randomized, placebo-controlled trial in 168 patients with mild Alzheimer’s disease and biomarkers of inflammation. Additional analysis...
-
Company to introduce design of upcoming Phase 2 study of XPro1595 in Alzheimer’s disease, which is expected to commence this year Boca Raton, FL, July 19, 2021 (GLOBE NEWSWIRE) --...
-
Boca Raton, FL., July 14, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that harness...
-
Boca Raton, FL, July 12, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
-
Purchase of Xencor Option potentially eliminates approximately 2.1 million shares of INmune future common stock dilution upon execution. LA JOLLA, Calif, June 14, 2021 (GLOBE NEWSWIRE) -- ...
-
LA JOLLA, Calif, June 02, 2021 (GLOBE NEWSWIRE) -- -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
-
LA JOLLA, Calif, May 24, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
-
LA JOLLA, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
-
LA JOLLA, Calif, April 28, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a...